T-Cell Engagers in Solid Tumors: Clinical Proof and Platform Competition | Oncology Modality Intelligence

Description

List of Tables

T-cell engagers spent a decade as hematology's tool - powerful against blood cancers, defeated by solid tumors. Tarlatamab changed the premise. Amgen's DLL3XCD3 bispecific became the first T-cell engager approved for a solid tumor, converting small-cell lung cancer from a graveyard for the modality into its proof of concept, and the question is no longer whether TCEs can work in solid disease but which targets, which constructs, and which treatment settings come next. The competitive field has organized itself quickly. Amgen is extending with xaluritamig against STEAP1 in prostate cancer. Boehringer Ingelheim's obrixtamig pursues DLL3 across neuroendocrine tumors. Merck & Co bought Harpoon Therapeutics in January 2024 for its TriTAC platform. Astellas, with Xencor's XmAb technology, is developing ASP2138 against CLDN18.2 - a target where Japan already holds first-in-world approval experience - while Innovent runs a parallel Chinese program. Regeneron is testing whether costimulatory CD28 bispecifics can unlock checkpoint combinations in PSMA- and EGFR-expressing tumors. The unresolved problems are the ones that have always defined the class: cytokine-release syndrome management and its staffing burden, step-up dosing logistics, on-target off-tumor toxicity when the target lives on healthy tissue, and treatment duration. For Japan these are adoption variables, not abstractions - CRS infrastructure and hospitalization capacity will gate uptake as surely as approval does, and Japan's trial-access geography will decide how early Japanese patients reach the next programs. This report maps the modality end to end: the tarlatamab precedent and its Japan status, the target-by-target pipeline across DLL3, STEAP1, PSMA, CLDN18.2, and others, platform competition among Amgen, Roche, J&J, Merck, Regeneron, and the Chinese entrants, the CRS-management and infrastructure question in Japanese hospitals, and the combination strategies that could move TCEs earlier in treatment. It serves oncology business-development teams, hematology-oncology operators planning infrastructure, and investors weighing the class after its first solid-tumor proof.

Scope and Coverage

The report covers the tarlatamab precedent, solid-tumor TCE targets and platforms, named programs and deals, CRS-management and hospitalization requirements, Japan trial access and adoption infrastructure, and combination strategies, with hematology TCE experience as context.

Report Highlights

Tarlatamab as the solid-tumor TCE proof of concept and its Japan pathway
Target map: DLL3, STEAP1, PSMA, CLDN18.2, EGFR, and emerging antigens
Platform competition: Amgen BiTE, Merck/Harpoon TriTAC, Roche CrossMab, Xencor XmAb, Regeneron costimulatory designs
ASP2138 and the CLDN18.2XCD3 frontier with Japanese development involvement
CRS-management infrastructure as Japan's adoption variable
Combination and earlier-line strategies for solid-tumor TCEs

Product Code: JPH-105

Table of Content

1. Executive Summary

2. T-Cell Engagers in Solid Tumors: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

Amgen (US) - tarlatamab (Imdelltra), the first solid-tumor T-cell engager, with full US approval (Nov 2025) and Japan authorization; xaluritamig (STEAP1XCD3) in Phase 3
Astellas (JP) - ASP2138 CLDN18.2XCD3 with Xencor; Japan TCE development footprint
Xencor (US) - XmAb TCE platform behind ASP2138 and other partnered programs
Innovent (CN) - IBI389 CLDN18.2XCD3 in the China clinic; DLL3 pipeline
Boehringer Ingelheim (DE) - obrixtamig (BI 764532) DLL3XCD3 in SCLC and neuroendocrine tumors
Merck & Co (US) - Harpoon Therapeutics acquisition (Jan 2024); HPN328 DLL3 TriTAC program
Roche (CH) - CrossMab TCE platform and solid-tumor bispecific pipeline
Johnson & Johnson (US) - TCE franchise expansion from myeloma into solid tumors
Regeneron (US) - REGN5678 (PSMAXCD28) and REGN7075 (EGFRXCD28) costimulatory bispecific strategy
BeiGene (CN) - tarlatamab China rights via the Amgen alliance
Akeso (CN) - cadonilimab and ivonescimab IO backbones as TCE combination partners in China

Product Code: JPH-105

List of Tables

Table 1. T-cell engager modality primer: mechanism, formats, and the hematology precedent
Table 2. Tarlatamab (Imdelltra) development and approval history in small-cell lung cancer
Table 3. Tarlatamab Japan regulatory status and pathway
Table 4. DeLLphi program structure: the trial series behind tarlatamab
Table 5. Amgen xaluritamig (STEAP1XCD3): Phase 3 prostate program design
Table 6. Boehringer Ingelheim obrixtamig (BI 764532): DLL3 program in SCLC and neuroendocrine tumors
Table 7. Merck & Co acquisition of Harpoon Therapeutics (2024) and the HPN328 TriTAC program
Table 8. Roche CrossMab TCE platform and solid-tumor pipeline
Table 9. Johnson & Johnson TCE franchise expansion from myeloma toward solid tumors
Table 10. Regeneron costimulatory strategy: REGN5678 (PSMAXCD28) and REGN7075 (EGFRXCD28)
Table 11. Astellas ASP2138 (CLDN18.2XCD3): design and development status
Table 12. Xencor XmAb platform contributions to partnered TCE programs
Table 13. Innovent IBI389 (CLDN18.2XCD3) and the Chinese DLL3 pipeline
Table 14. BeiGene's China rights to tarlatamab under the Amgen alliance
Table 15. Emerging solid-tumor TCE targets: B7-H3, MUC17, GPC3, and others
Table 16. Half-life extension and dosing-format competition across platforms
Table 17. Step-up dosing regimens and their operational requirements
Table 18. Cytokine-release syndrome: grading, management protocols, and staffing models
Table 19. On-target off-tumor toxicity patterns by target class
Table 20. Treatment-duration and discontinuation strategy across TCE programs
Table 21. CLDN18.2 target context in Japan: the Vyloy first-in-world precedent
Table 22. Small-cell lung cancer treatment landscape in Japan and TCE positioning
Table 23. Prostate cancer TCE development context: PSMA and STEAP1 programs
Table 24. Neuroendocrine tumor opportunity for DLL3-directed engagers
Table 25. Gastric and pancreatic applications of CLDN18.2-directed TCEs
Table 26. Combination strategies pairing TCEs with PD-(L)1 inhibitors
Table 27. Costimulatory-bispecific combination logic: CD28 constructs with CD3 engagers
Table 28. Earlier-line and perioperative development concepts for solid-tumor TCEs
Table 29. Japan trial-access geography across solid-tumor TCE programs
Table 30. CRS-capable hospital infrastructure in Japan: current distribution
Table 31. Hematology TCE operational experience in Japan as a template
Table 32. Bispecific-versus-CAR-T competition dynamics in Japanese practice
Table 33. PMDA review considerations for solid-tumor TCE filings
Table 34. Outpatient-administration pathways and their Japanese feasibility
Table 35. Nursing and monitoring protocol requirements for TCE initiation
Table 36. Deal and partnership activity in solid-tumor TCEs, 2023-2026
Table 37. Competitive-position matrix of solid-tumor TCE programs by target
Table 38. Scenario grid for TCE expansion beyond small-cell lung cancer
Table 39. Scenario grid for CLDN18.2 modality competition: antibody, ADC, CAR-T, and TCE
Table 40. NHI pricing considerations for bispecific antibodies in solid tumors
Table 41. Risk register for companies developing solid-tumor TCEs
Table 42. Risk register for Japanese hospitals building TCE capability
Table 43. Key opinion leader landscape in Japanese thoracic and GI oncology for TCEs
Table 44. Patient-selection and biomarker requirements across TCE targets
Table 45. Watchlist of solid-tumor TCE readouts and filings, 2026-2028
Table 46. Stakeholder map: developers, hospitals, societies, and payers
Table 47. Technology-assessment framework for TCE platforms
Table 48. Infrastructure-investment framework for Japanese TCE adoption
Table 49. Lessons from hematology TCE rollout applicable to solid tumors
Table 50. Timeline of solid-tumor TCE development with Japan milestones, 2021-2026

List of Figures

Figure 1. T-cell engager mechanism schematic in solid tumors
Figure 2. Hematology-to-solid-tumor arc of the TCE modality
Figure 3. Tarlatamab development and approval pathway
Figure 4. DeLLphi program map behind tarlatamab
Figure 5. Xaluritamig Phase 3 prostate program structure
Figure 6. Obrixtamig DLL3 program footprint across neuroendocrine tumors
Figure 7. Merck-Harpoon acquisition and the TriTAC platform (2024)
Figure 8. Roche CrossMab solid-tumor TCE pipeline map
Figure 9. J&J TCE expansion path from myeloma to solid tumors
Figure 10. Regeneron CD28 costimulatory combination architecture
Figure 11. ASP2138 CLDN18.2XCD3 design and development plan
Figure 12. Xencor XmAb platform map across partnered programs
Figure 13. Chinese CLDN18.2 and DLL3 TCE programs: Innovent and peers
Figure 14. BeiGene China tarlatamab arrangement under the Amgen alliance
Figure 15. Emerging target map for solid-tumor TCEs
Figure 16. Half-life and dosing-format competition across platforms
Figure 17. Step-up dosing operational flow
Figure 18. CRS management protocol schematic
Figure 19. On-target off-tumor toxicity map by target class
Figure 20. Treatment-duration strategy options across TCE programs
Figure 21. CLDN18.2 modality landscape anchored by the Vyloy precedent
Figure 22. SCLC treatment pathway in Japan with TCE positioning
Figure 23. Prostate TCE development context: PSMA and STEAP1
Figure 24. DLL3 opportunity in neuroendocrine tumors
Figure 25. GI applications of CLDN18.2-directed TCEs
Figure 26. TCE-checkpoint combination logic
Figure 27. CD28-plus-CD3 combination architecture
Figure 28. Earlier-line development concepts for solid-tumor TCEs
Figure 29. Japan trial-access map across TCE programs
Figure 30. CRS-capable hospital infrastructure distribution in Japan
Figure 31. Hematology TCE operations as an adoption template
Figure 32. Bispecific-versus-CAR-T dynamics in Japanese practice
Figure 33. PMDA review pathway for solid-tumor TCE filings
Figure 34. Outpatient-administration feasibility pathway in Japan
Figure 35. Nursing and monitoring requirements for TCE initiation
Figure 36. Solid-tumor TCE deal map, 2023-2026
Figure 37. Competitive-position matrix by target and platform
Figure 38. TCE expansion scenario tree beyond SCLC
Figure 39. CLDN18.2 modality-competition scenario tree
Figure 40. NHI pricing frame for solid-tumor bispecifics
Figure 41. Risk map for solid-tumor TCE developers
Figure 42. Risk map for Japanese hospitals building TCE capability
Figure 43. Japanese thoracic and GI oncology KOL landscape for TCEs
Figure 44. Biomarker and patient-selection requirements by target
Figure 45. Solid-tumor TCE readout and filing calendar, 2026-2028
Figure 46. Stakeholder map across developers, hospitals, societies, and payers
Figure 47. TCE platform technology-assessment framework
Figure 48. Infrastructure-investment framework for Japanese adoption
Figure 49. Hematology rollout lessons applied to solid tumors
Figure 50. Solid-tumor TCE development timeline with Japan milestones, 2021-2026

T-Cell Engagers in Solid Tumors: Clinical Proof and Platform Competition | Oncology Modality Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. T-Cell Engagers in Solid Tumors: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures